LL-37: A Human Cathelicidin Antimicrobial Peptide — Research Overview
LL-37: A Human Cathelicidin Antimicrobial Peptide — Research Overview
LL-37 is a 37-amino acid peptide beginning with two leucine (L) residues, derived from the C-terminal cleavage of human cathelicidin antimicrobial protein-18 (hCAP18, also known as CAMP). It is the only member of the cathelicidin family identified in humans. hCAP18 is produced by neutrophils, monocytes, epithelial cells, and other cell types, and is cleaved by serine proteases (primarily proteinase 3 in neutrophils) to release the active LL-37 fragment. Since its characterization in the 1990s, LL-37 has emerged as one of the most studied host defense peptides in immunology research (Vandamme et al., Cellular Immunology, 2012; PMID: 22421098).
Mechanism of Action
LL-37 is classified as an amphipathic alpha-helical antimicrobial peptide, and its mechanism of action involves multiple immunological functions:
Direct antimicrobial activity: LL-37 adopts an amphipathic alpha-helical structure in the presence of biological membranes or lipid environments. The cationic, amphipathic structure enables electrostatic interaction with negatively charged microbial membranes (which are enriched in phosphatidylglycerol and lipopolysaccharide), leading to membrane disruption. This mechanism provides broad-spectrum activity against gram-positive and gram-negative bacteria, fungi, and enveloped viruses in vitro (Vandamme et al., Cellular Immunology, 2012; PMID: 22421098).
LPS neutralization: LL-37 directly binds and neutralizes lipopolysaccharide (LPS), a potent immune activator released from gram-negative bacterial cell walls. By sequestering LPS, LL-37 can modulate the inflammatory cascade triggered by bacterial components — functioning as an endogenous anti-endotoxin agent in preclinical models.
Immune cell chemotaxis: LL-37 acts as a chemoattractant for neutrophils, monocytes, and T-cells through interaction with formyl peptide receptor-like 1 (FPRL1/FPR2). This chemotactic function links LL-37 to the recruitment of immune cells to sites of infection or tissue damage (De et al., Journal of Experimental Medicine, 2000; PMID: 10952724).
Immunomodulation: Beyond its direct antimicrobial effects, LL-37 modulates immune cell function through multiple mechanisms: promoting dendritic cell differentiation, influencing macrophage polarization, modulating cytokine production (including effects on IL-1β, TNF-α, and IL-10), and serving as a danger signal (alarmin) that activates the innate immune response.
Wound healing: In cell culture and animal models, LL-37 has been observed to promote wound healing through stimulation of epithelial cell migration, angiogenesis (via VEGF induction), and extracellular matrix remodeling (Heilborn et al., Journal of Investigative Dermatology, 2003; PMID: 12780965).
Published Research
Antimicrobial spectrum: Extensive in vitro studies have characterized LL-37's antimicrobial activity against a wide panel of clinically relevant microorganisms. Minimum inhibitory concentration (MIC) studies have demonstrated activity in the low micromolar range against both gram-positive (including Staphylococcus aureus) and gram-negative (including Pseudomonas aeruginosa) species, as well as fungal organisms (Vandamme et al., Cellular Immunology, 2012; PMID: 22421098).
Endotoxin neutralization: Studies demonstrated that LL-37 binds LPS with high affinity and can reduce LPS-induced cytokine production in cell culture models. This anti-endotoxin activity has been the focus of research examining LL-37's role in modulating the host inflammatory response to bacterial products.
Immune cell recruitment: De et al. demonstrated that LL-37 induced chemotaxis of neutrophils, monocytes, and CD4+ T-cells through FPRL1 receptor activation, establishing LL-37 as a multifunctional molecule that bridges antimicrobial defense and immune cell mobilization (De et al., Journal of Experimental Medicine, 2000; PMID: 10952724).
Tissue repair: In wound healing studies, Heilborn et al. observed that LL-37 was abundantly present in wound fluid and that its expression was upregulated in migrating wound-edge keratinocytes. Exogenous LL-37 application was associated with accelerated re-epithelialization in cell migration assays (Heilborn et al., Journal of Investigative Dermatology, 2003; PMID: 12780965).
Biofilm research: LL-37 has been investigated for its activity against bacterial biofilms — structured microbial communities that are highly resistant to conventional antimicrobial agents. Studies have observed that LL-37 can inhibit biofilm formation and disrupt pre-formed biofilms at sub-MIC concentrations.
Purity and Quality Considerations
LL-37 is a 37-amino acid peptide, making it one of the longer peptides commonly used in research. Its synthesis requires careful attention to aggregation, which can occur during purification due to LL-37's amphipathic nature. Researchers should verify purity ≥95% by HPLC, confirm molecular weight (4,493 Da) by mass spectrometry, and ensure proper reconstitution protocols to avoid aggregation artifacts. Learn more about peptide purity testing and quality standards.
Research Resources
LL-37 is not currently available in the CALM Peptides catalog. For related immune peptides, browse our immune category, including Thymosin Alpha-1 and Thymalin. Explore our full catalog.
Frequently Asked Questions
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid peptide cleaved from the precursor protein hCAP18. It is studied in preclinical models for its broad antimicrobial activity, immunomodulatory functions, and roles in wound healing.
Why is LL-37 considered multifunctional?
LL-37 has been observed to function simultaneously as a direct antimicrobial agent (membrane disruption), an immune modulator (cytokine regulation, dendritic cell maturation), a chemotactic factor (immune cell recruitment via FPRL1), an endotoxin neutralizer (LPS binding), and a wound healing promoter (epithelial migration, angiogenesis).
What is the cathelicidin family?
Cathelicidins are a family of host defense proteins found across vertebrate species. Humans produce a single cathelicidin (hCAP18), from which LL-37 is the active antimicrobial fragment. Other species produce multiple cathelicidins with diverse structures and functions.
How does LL-37 kill microorganisms?
LL-37 adopts an amphipathic alpha-helical structure that allows it to interact with and disrupt negatively charged microbial membranes. This electrostatic mechanism provides broad-spectrum activity against bacteria, fungi, and enveloped viruses in laboratory studies.
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. LL-37 is described here for educational purposes as part of immunology research literature. It is not intended for human consumption, and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.
For research use only. Not for human consumption.
Related Reading: What Are Peptides? · Immune Peptides · Thymosin Alpha-1 Research Overview · Thymalin Research Overview · BPC-157 Research Overview · Quality & Purity Standards
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. All products referenced are sold as research chemicals for laboratory use only. They are not intended for human consumption and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.